Cyclerion Therapeutics (NASDAQ:KRSA) Stock Bumped Up to “Sell” by Wall Street Zen

Wall Street Zen upgraded shares of Cyclerion Therapeutics (NASDAQ:KRSA) to a sell rating in a research note published on Saturday,Wall Street Zen reports.

Several other equities analysts have also commented on the company. Stifel Nicolaus initiated coverage on Cyclerion Therapeutics in a research note on Monday, September 14th. They issued a “buy” rating and a $43.00 price target on the stock. Guggenheim began coverage on shares of Cyclerion Therapeutics in a research note on Monday, September 28th. They issued a “buy” rating and a $70.00 price target for the company. UBS Group assumed coverage on Cyclerion Therapeutics in a research report on Friday, September 11th. They set a “buy” rating and a $55.00 price objective for the company. Zacks Research raised Cyclerion Therapeutics to a “hold” rating in a report on Wednesday, September 9th. Finally, TD Cowen began coverage on shares of Cyclerion Therapeutics in a research note on Monday, September 14th. They issued a “buy” rating on the stock. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $56.00.

Cyclerion Therapeutics Price Performance

Shares of NASDAQ KRSA opened at $30.49 on Friday. The company has a market cap of $20.43 million, a PE ratio of -2.62 and a beta of 1.72. Cyclerion Therapeutics has a 1 year low of $7.19 and a 1 year high of $59.36.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases with substantial unmet medical needs. The company was established in 2019 as a spinout from Ironwood Pharmaceuticals and built its research portfolio around soluble guanylate cyclase (sGC) stimulation, a mechanism involved in regulating blood flow and cellular signaling.

Cyclerion’s development programs included olinciguat, an investigational therapy studied in sickle cell disease and other vascular conditions; praliciguat, an sGC stimulator evaluated for cardiometabolic and renal diseases; and IW-6463, a central nervous system-penetrant sGC stimulator investigated for neurological disorders.